Although Aβ is a core biomarker of preclinical Alzheimer's pathology, a more definitive assessment of this stage requires evaluating tau pathology and the synergistic toxic effects of Aβ and tau, also in relation to the evaluation of the clinical AD progression pathway. Here, MAPT is linked to Alzheimer disease.